» Articles » PMID: 16648484

Persistent Transactivation by Meis1 Replaces Hox Function in Myeloid Leukemogenesis Models: Evidence for Co-occupancy of Meis1-pbx and Hox-pbx Complexes on Promoters of Leukemia-associated Genes

Overview
Journal Mol Cell Biol
Specialty Cell Biology
Date 2006 May 2
PMID 16648484
Citations 52
Authors
Affiliations
Soon will be listed here.
Abstract

Homeobox transcription factors Meis1 and Hoxa9 promote hematopoietic progenitor self-renewal and cooperate to cause acute myeloid leukemia (AML). While Hoxa9 alone blocks the differentiation of nonleukemogenic myeloid cell-committed progenitors, coexpression with Meis1 is required for the production of AML-initiating progenitors, which also transcribe a group of hematopoietic stem cell genes, including Cd34 and Flt3 (defined as Meis1-related leukemic signature genes). Here, we use dominant trans-activating (Vp16 fusion) or trans-repressing (engrailed fusion) forms of Meis1 to define its biochemical functions that contribute to leukemogenesis. Surprisingly, Vp16-Meis1 (but not engrailed-Meis1) functioned as an autonomous oncoprotein that mimicked combined activities of Meis1 plus Hoxa9, immortalizing early progenitors, inducing low-level expression of Meis1-related signature genes, and causing leukemia without coexpression of exogenous or endogenous Hox genes. Vp16-Meis1-mediated transformation required the Meis1 function of binding to Pbx and DNA but not its C-terminal domain (CTD). The absence of endogenous Hox gene expression in Vp16-Meis1-immortalized progenitors allowed us to investigate how Hox alters gene expression and cell biology in early hematopoietic progenitors. Strikingly, expression of Hoxa9 or Hoxa7 stimulated both leukemic aggressiveness and transcription of Meis1-related signature genes in Vp16-Meis1 progenitors. Interestingly, while the Hoxa9 N-terminal domain (NTD) is essential for cooperative transformation with wild-type Meis1, it was dispensable in Vp16-Meis1 progenitors. The fact that a dominant transactivation domain fused to Meis1 replaces the essential functions of both the Meis1 CTD and Hoxa9 NTD suggests that Meis-Pbx and Hox-Pbx (or Hox-Pbx-Meis) complexes co-occupy cellular promoters that drive leukemogenesis and that Meis1 CTD and Hox NTD cooperate in gene activation. Chromatin immunoprecipitation confirmed co-occupancy of Hoxa9 and Meis1 on the Flt3 promoter.

Citing Articles

Modification of Lhx2 activity for amplification of human iPSC-derived hematopoietic stem/progenitor cells.

Kitajima K, Takahashi Y, Ando H, Shingai M, Hamasaki M, Tanikawa M Front Cell Dev Biol. 2024; 12:1482989.

PMID: 39474350 PMC: 11518812. DOI: 10.3389/fcell.2024.1482989.


NUP98 oncofusions in myeloid malignancies: An update on molecular mechanisms and therapeutic opportunities.

Rasouli M, Troester S, Grebien F, Goemans B, Zwaan C, Heidenreich O Hemasphere. 2024; 8(9):e70013.

PMID: 39323480 PMC: 11423334. DOI: 10.1002/hem3.70013.


Systematic characterization of the HOXA9 downstream targets in MLL-r leukemia by noncoding CRISPR screens.

Wright S, Zhao X, Rosikiewicz W, Mryncza S, Hyle J, Qi W Nat Commun. 2023; 14(1):7464.

PMID: 38016946 PMC: 10684515. DOI: 10.1038/s41467-023-43264-5.


The NCOR-HDAC3 co-repressive complex modulates the leukemogenic potential of the transcription factor ERG.

Kugler E, Madiwale S, Yong D, Thoms J, Birger Y, Sykes D Nat Commun. 2023; 14(1):5871.

PMID: 37735473 PMC: 10514085. DOI: 10.1038/s41467-023-41067-2.


Mutant NPM1 Directly Regulates Oncogenic Transcription in Acute Myeloid Leukemia.

Uckelmann H, Haarer E, Takeda R, Wong E, Hatton C, Marinaccio C Cancer Discov. 2022; 13(3):746-765.

PMID: 36455613 PMC: 10084473. DOI: 10.1158/2159-8290.CD-22-0366.


References
1.
Schnabel C, Jacobs Y, Cleary M . HoxA9-mediated immortalization of myeloid progenitors requires functional interactions with TALE cofactors Pbx and Meis. Oncogene. 2000; 19(5):608-16. DOI: 10.1038/sj.onc.1203371. View

2.
Janssen E, Zhu M, Zhang W, Koonpaew S, Zhang W . LAB: a new membrane-associated adaptor molecule in B cell activation. Nat Immunol. 2003; 4(2):117-23. DOI: 10.1038/ni882. View

3.
Afonja O, Smith Jr J, Cheng D, Goldenberg A, Amorosi E, Shimamoto T . MEIS1 and HOXA7 genes in human acute myeloid leukemia. Leuk Res. 2000; 24(10):849-55. DOI: 10.1016/s0145-2126(00)00059-x. View

4.
Calvo K, Sykes D, Pasillas M, Kamps M . Nup98-HoxA9 immortalizes myeloid progenitors, enforces expression of Hoxa9, Hoxa7 and Meis1, and alters cytokine-specific responses in a manner similar to that induced by retroviral co-expression of Hoxa9 and Meis1. Oncogene. 2002; 21(27):4247-56. DOI: 10.1038/sj.onc.1205516. View

5.
Giovannini M, Biegel J, Serra M, Wang J, Wei Y, Nycum L . EWS-erg and EWS-Fli1 fusion transcripts in Ewing's sarcoma and primitive neuroectodermal tumors with variant translocations. J Clin Invest. 1994; 94(2):489-96. PMC: 295111. DOI: 10.1172/JCI117360. View